MIRD pamphlet No. 15: Radionuclide S values in a revised dosimetric model of the adult head and brain

Journal of Nuclear Medicine

Volumn 40, Issue 3, 1999, Pages

  Bouchet, Lionel G ^b   Bolch, Wesley E ^a   Weber, David A ^b   Atkins, Harold L ^b   Poston Sr , John W ^b   Brill, A B ^b   Charkes, N D ^b   Fisher, D R ^b   Hays, M T ^b   Howell, R W ^b   Robertson, J S ^b   Siegel, J A ^b   Thomas, S R ^b   Watson, E E ^b   Wessels, B W ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE

Author keywords

Brain dosimetry; MIRD schema; Neuroimaging; Suborgan dosimetry

Indexed keywords

RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TROPANE I 123; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN; BRAIN REGION; DOSIMETRY; ELECTRON; HEAD; HUMAN; MATHEMATICAL MODEL; NEURORADIOLOGY; PHOTON; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BRAIN; COMPUTER SIMULATION; HEAD; HUMANS; MODELS, THEORETICAL; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 0033059292     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. London ED Imaging drug action in the brain. Boca Raton. FL: CRC Press; 1993.
2. Saha GB, MacIntyre WJ. Go RT Radiopharmacceuticals for brain imaging. Semin Nucl Med 1994;24:124-349
3. Messa C, Fazio F. Costa DC. Ell PJ. Clinical brain radionuclide imaging studies. Semin Nucl Med 1995;25:111-143.
4. Ell PJ, Jarritt PH, Costa DC, Cullum ID. Lui D. Functional imaging of the brain, Semin Nucl Med 1987;17:214-229.
5. van Heertum RL. Tikofsky RS. Cerebral SPECT imaging. 2nd ed. New York: Raven Press, 1995.
6. Snyder WS, Ford MR, Warner GG, Fisher HL, Jr. Estimates of absorbed tractions for monoenergetu photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No. 5. New York: Society of Nuclear Medicine: 1969.
7. Snyder WS. Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom, MIRD Pamphlet No. 5 Revised. New York: Society of Nuclear Medicine: 1978.
8. Cristy M. Mathematical phantoms representing children of various ages for use in estimates of internal dose. ORNL NUREG TM-367. Oak Ridge. TN: Oak Ridge National Laboratory; 1980.
9. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL TM-8381 Volumes I VII. Oak Ridge, TN: Oak Ridge National Laboratory; 1987.
10. Matsuda H. Li YM, Higashi S, et al. Comparative SPECT study of stroke using Tc-99m ECD. 1-123 IMP, and Tc-99m HMPAO. Clin Nucl Med 1993;18:754-758.
11. 99mTc-HMPAO in healthy volunteers. Kaku IgaKu 1994;31:423-429.
12. Devous MD Sr., Payne JK, Lowe JL, Leroy RF. Comparison of technetium-99m-ECD to xenon-133 SPECT in normal controls and in patients with mild to moderate regional cerebral blood flow abnormalities. J Nucl Med 1993;34:754-761.
13. Vallabhajosula S, Zimmerman RE. Picard M, et al. Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 1989;30:599-604.
14. Baldwin RM. Iofetamme HCI I 1-123 (IMP). In: Weber DA, Devous MD Sr., Tikofsky RS, Woodhead AD, Vivirilo KJ, eds. Brain SPECT perfusion imaging: image acquisition, processing, display, and interpretation. CONF-9110368. Brookhaven National Laboratory. United States Department of Energy: 1992:1 -7.
15. Steinling M, Mazingue A, Rousseaux M, et al. Computerized tomography of the distribution of N-isopropyl-p-123 iodoamphetamine in cerebrovascular pathology. Comparison with studies using the 133-xenon inhalation method. Acta Neurol Belg 1987;87:113-124.
16. Weber DA. Eranceschi D, Ivanovic M. et al. SPECT and planar brain imaging in crack abuse: iodine-123-iodoamphetamine uptake and localization. J Nucl Med 1993;34: 899-907.
17. Volkow ND, Mullani N, Gould LK, Adler SS. Galley SJ. Sensitivity of measurements of regional brain activation with oxygen-15-water and PET to time of stimulation and period of image reconstruction, J Nucl Med 1991;32:58-61.
18. Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with 0-15 radiotracers and positron emission tomography. J Nucl Med 1984;25:177-187.
19. Shishido F, Uemura K, Inugami A. Nagata K. Hirata Y. Measurement of cerebral cirulation and metabolism in patients with spinocerebellar degeneration using positron emission tomography and O-15 steady-state method. Kaku Igaku 1988;25:633-638
20. Brihaye C, Depresseux JC, Comar D. Radiation dosimetry for bolus administration of oxygen-15-water. J Nucl Med 1995;36:651-656.
21. Smith T, Tong C, Lammertsma AA, et al. Dosimetry of intravenously administered oxygen-15 labelled water in man: a model based on experimental human data from 21 subjects. Eur J Nucl Med 1994:21:1126-1134
22. 15O. J Nucl Med 1982;23:1031-1037.
23. 15O] water: a physiologic approach. Med Phys 1996;23:159-168.
24. Tran Dinh YR, Ille O, Guichard JP, Haguenau M, Seylaz J. Cerebral postischemic hyperfusion assessed by xenon-133 SPECT. J Nucl Med 1997;38:602-607.
25. Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connolly BT, Atkins HL. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987;28:47-52.
26. Kim KT, Black KL, Marciano D, et al. Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med 1990:31:965-969.
27. Kline JL, Noto RB, Glantz M. Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy. Am J Neuroradiol 1996;17:1681-1686.
28. Park CH, Sataloff R, Richard M. Zhang J. Kim SM. Tc-99m MIBI brain SPECT of cerebellopontine angle tumors, Clin Nucl Med 1996;21:375-378.
29. O'Tuama LA, Packard AB, Treves ST. SPECT imaging of pediatric brain tumor with hexakis (methoxyisobutylisomtrile) technetium (I). J Nucl Med 1990;31:2040-2041.
30. Barth A, Haldemann AR, Reubi JC. et al. Noninvasive differentiation of meningiomas from other brain tumours using combined 111-indium-octreotide,99m-technelium-DTPA brain scinligraphy. Acta Neurochir 1996;138:1179-1185
31. 99mTc DTPA as brain imaging agents. Radiology 1997;123:379-383.
32. Biersack HJ, Coener. HH, Stöcklin G, et al. Imaging of brain tumors with L-3-[123-I]iodo-alpha-methyl tyrosme and SPECT. J Nucl Med 1989;30:110-112.
33. Weber W, Bartensteiri P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPEC T in the evaluation of brain tumors. J Nucl Med 1997;38:802-808.
34. 123]iodo-α-methyl tyrosine: competition with natural L-ammo acids. J Nucl Med 1991;32:1225-1229.
35. 11C-methionine. Am J Neuroradiol 1996;17:345-353.
36. Oriuchi N, Tomiyoshi K. Inouc T, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 1996;37:457-462.
37. Schober O, Meyer GJ. Duden C, et al. Amino acid uptake in brain tumors using positron emission tomography as an indicator for evaluating metabolic activity and malignancy, Fortschr Geb Rontenstr Nuklearmed 1987;147:503-501.
38. 11C]L-methionine uptake in gliomas. Neurasurgery 1989;25:720-728.
39. 11C]NMPBI), a muscarine acetylcholine receptor anatagonist. Nucl Med Biol 1995;22:13-17
40. Sparks RB. Dey HM. Seibyl JB, Inms RB, Stubbs JB. Radiation dose estimates for C-11 iomazenil, a benzodiazepine receptor radioligand J Nucl Med 1994;35:159P.
41. Mozley PD, Stubbs JB, Kim HJ. et al. Dosimetry of a D2 D3 dopamine receptor anatagonist that can be used with PET or SPECT. J Nucl Med 1995;36:1322-1331.
42. Seibyl J, Wallace E, Smith EO, et al. Whole body biodistribution. radiation absorbed dose, and brain SPECT imaging with iodine-123-β-CIT in healthy human subjects. J Nucl Med 1994;35:764-770.
43. 123]epidepride single-photon emission tomography. Eur J Nucl Med 1997:24:483-487
44. MozlEy PD. Stubbs JB, Kung MF, Selikson MH. Stabin MG. Alavi A. Biodistribution and dosimetry of iodine-123 IBF: a potent radioligand for-imaging the D2 dopamine receptor. J Nucl Med 1993:34:1910-1917.
45. Mozley PD. Zhu X. Kung HF. et al. The dosimetry of iodine-123 TISCH: a SPECT agent for the Dl dopamine receptor. J Nucl Med 1993;34:208-213.
46. Nishizama S, Tanada S, Yonckura Y. et al. Regional dynamics of N-isopropyl-p-[123l]iodoamphetamine in human brain. J Nucl Med 1989;30:150-156.
47. 123I]IBF, Nucl Med Biol 1996:23:9-16.
48. Votaw JR, Ansan MS, Mason NS, et al. Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand. J Nuxl Med 1995:36:1316-1321.
49. Verhoeff NP, Sokole EB. Stabin M, et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med 1993;20:747-752.
50. Verhoeff NP, Busemann Sokole E, Hengst D. Stubbs JB, van Royen EA. Dosimetry of iodine-123 iomazenil in humans. Eur J Nucl Med 1993:20:580-584.
51. Bouchet LG, Bolch WE, Weber DA. Atkins HL. Poston JW. A revised dosimetric model of the adult head and brain. J Nucl Med 1996;37:1226-1236
52. Schnitzlein HN, Murtagh FR. Imaging anatomy of the head and spine: a photographic color atlas of MRI, CT. gross-, and microscopic anatomy in axial, coronal and sagittal planes, 2nd ed. Baltimore: Urban & Schwarzenberg; 1990.
53. ICRP. Report on the task group on reference man. ICRP Publication 23. Oxford. England: International Commission on Radiological Protection: 1975.
54. Hwang JML. Shoup RL, Warner GG. Poston JW. Mathematical description of a one-and five-year-old child for use in dosimerry calculations. ORNL'TM-5293. Oak Ridge. TN: Oak Ridge National Laboratory: 1976.
55. Jones RM. Poston JW, Hwang JL, Jones TD, Warner GG. The development and use of u fiifteen-year-old equivalent mathematical phantom for internal dose calculations. ORNLTM-5278. Oak Ridge. TN: Oak Ridge National Laboratory; 1976.
56. Hwang JML, Shoup RL, Poston JW. Mathematical description of a newhorn human for use in dosimetn calculations. ORNL TM-5453. Oak Ridge. TN: Oak Ridge National Laboratory: 1976.
57. Hwang JML. Shoup RL, Poston JW. Modifications and additions to the pediatric and adult mathematical phantoms. ORNL TM-5454. Oak Ridge, TN: Oak Ridge National Laboratory; 1976
58. Beck TJ, Rosenstein M. Quantification of current practice in pediatric roentgenograptlv for organ Dose calculations, FDA Report No. 79-8078. Washington. DC: Food and Drug Administration: 1979.
59. Rosenstein M, Beck TJ, Wamer GG. Handbook of selected organ doses for projections common in pediatric radiology. FDA Report No. 79-8079. Washington. DC: Food and Drug Administration: 1979.
60. Chen WL, Poston JW. Warner GG. An evaluation of the distribution of absorbed dose in child phantoms exposed to diagnostic medical x-rays, ORNL TM-5933. Oak Ridge, TN: Oak Ridge National Laboratory; 1978.
61. Eckerman KF, Cristy M, Wamer GG. Dosimetric evaluation of brain scanning agents. In: Watson EE, Schlafke-Stelson AT. Coffey JL. Cloutier RJ. eds. Proceedings of the third international rudiopharmaceittical dositnelry symposium. HHS Publication FDA 81-8166. Oak Ridge, TN: Oak Ridge Associated Universities: 1980:527-540.
62. Bouchel LG. A new head and brain dosimetry model [Masters' Thesis]. College Station, TX: Texas A&M University: 1995.
63. Johansson L, Nosslin B. Dosimetry of intrathecally administered radiopharmaceuticals. In: Watson EE. Schlalke-Stelson AT, eds. Proceedings of the fifth international raditfpharniaceutical dosimetry symposium. CONF-910529. Oak Ridge. TN: Oak Ridge Associated Universities: 1991:188-201.
64. Blinkov SM, Glezer II. The human brain in figures and tables. New York: Plenum Press; 1968
65. Tompsett DH, Last RJ. Casts of the cerebral ventricles. Br J Surg 1953:40:525-543.
66. Harman PJ, Carpenter MV. Volumetric comparisons of the basal ganglia of various primates including man. J Comp Neurol 1950;93:125-139.
67. Nelson WR, Hirayama RH. Roger DWO. The EGS4 code system. SLAC-265. Palo Alto, CA: Stanford Linear Accelerator Center; 1985.
68. Jenkins TM, Nelson WM, Rindi A. Monte Carlo transport of electrons and photons, International Science Series 38 New York: Plenum Press: 1988.
69. Eckerman KF. Westfall RJ, Ryman JC. Cristy M. Availability of nuclear decay data in electronic form, including beta spectra not previously published. Health Phys 1994 67:338-345.
70. Eckerman KF, Westfall RJ. Ryman JC, Cristy M. Nuclear decay Jam tiles of the dosimetry research group. ORM. TM-12350. Oak Ridge. TN: Oak Ridge National Laboratory; 1993.
71. Mozlcy PD. Kim H-J. Gur RC, et al. Iodine-123-IPT SPKT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med 1996;37:1965-1970.
72. Mozley PD, Stubbs JB, Kirn M-J. et al. Dosimetry of an iodine-1 23-laheled tropane to image dopamine transporters. J Nucl Med 1996:37:151-159.
73. Snyder WS, Ford MR. Warner GG. Watson SB. "S," abssorbed dose per unit cumulated activity for selected radionuclides and organs Pamphlet No. 11. New York: Society of Nuclear Medicine: 1975.
74. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-546.
75. Howell RW. Loevinger R. The MIRD perspective. J Nucl Med 1999:40:35-105.
76. Eckerman KF Aspects of the dosimetry of radionuclides within the skeleton with particular emphasis on the active marrow. In: Schlafke-Stelson AT, Watson HE, eds. Proceedings of the fourth intenational radiopharmaceutical dosimetry symposium. CONF-85113. Oak Ridge, TN: Oak Ridge Associated Universities. 1985;514-534.
77. O'Tuama LA. Bjornson B. Chugani H. Treves ST. Brain. In: Treves ST. eds. Pediatrics nuclear medicine. 2nd ed. New York: Springer-Verlag: 1995:88-108.